Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer

2/9/24 6:03:14 AM ET

$ADAG

$MRK

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADAG alert in real time by email

Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -

Initiated evaluation of 20 mg/kg loading doses of ADG126 in combination with pembrolizumab to explore enhanced efficacy given superior therapeutic index of ADG126 -

Received clearance from China's Center for Drug Evaluation (CDE) to evaluate ADG126 in combination with pembrolizumab -

Get the next $ADAG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADAG
$MRK

Company	Date	Price Target	Rating	Analyst
Merck & Company Inc. $MRK	11/15/2024		Peer Perform	Wolfe Research
Merck & Company Inc. $MRK	11/11/2024		Buy → Neutral	Daiwa Securities
Merck & Company Inc. $MRK	10/17/2024	$115.00	Mkt Perform	Bernstein
Merck & Company Inc. $MRK	3/11/2024	$104.00	Hold → Sell	Societe Generale
Merck & Company Inc. $MRK	1/4/2024	$125.00 → $135.00	Market Perform → Outperform	TD Cowen
Merck & Company Inc. $MRK	11/9/2023	$115.00	Buy	Deutsche Bank
Merck & Company Inc. $MRK	10/27/2023	$132.00	Market Perform → Outperform	BMO Capital Markets
Merck & Company Inc. $MRK	10/20/2023	$117.00 → $122.00	Neutral → Buy	UBS

More analyst ratings

$ADAG
$MRK
Press Releases

Fastest customizable press release news feed in the world

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
New research across a broad range of hematologic malignancies to be featured during the meeting, including presentations for investigational assets zilovertamab vedotin and nemtabrutinib Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company's continued progress in advancing clinical research for Merck's expanding and diverse pipeline of investigational candidates, with more than 20
11/21/24 6:45:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Merck Announces First-Quarter 2025 Dividend
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens
11/19/24 12:22:00 PM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck to discuss results from MK-3475A-D77 study with regulatory authorities worldwide Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck's anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahya
11/19/24 6:45:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a
3/7/24 4:01:00 PM ET
$ADAG
Biotechnology: Pharmaceutical Preparations
Health Care
Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
11/14/23 5:25:00 PM ET
$ASH
$MRK
Specialty Chemicals
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
5/18/23 8:00:00 AM ET
$ALLO
$AMGN
$MRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$ADAG
$MRK
Financials

Live finance-specific insights

Merck Announces First-Quarter 2025 Dividend
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens
11/19/24 12:22:00 PM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Merck Announces Third-Quarter 2024 Financial Results
Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining Momentum; Received Approval in the EU Animal Health Sales Grew 6% to $1.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 11% GAAP EPS Was $1.24; Non-GAAP EPS Was $1.57; GAAP and Non-GAAP EPS Include a Net Charge of $0.79 per Share Related to Certain Business Development Transactions Achieved Significant Milestones in Vaccine Programs CAPVAXIVE Recommended by t
10/31/24 6:30:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care

Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer

Chat with this insight

Recent Analyst Ratings for $ADAG$MRK

$ADAG$MRK Press Releases

Fastest customizable press release news feed in the world

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

Merck Announces First-Quarter 2025 Dividend

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

$ADAG$MRK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Adagene Inc.

SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

$ADAG$MRK Leadership Updates

Live Leadership Updates

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

$ADAG$MRK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on Merck

Merck downgraded by Daiwa Securities

Bernstein initiated coverage on Merck with a new price target

$ADAG$MRK SEC Filings

Amendment: SEC Form 6-K/A filed by Adagene Inc.

Amendment: SEC Form 6-K/A filed by Adagene Inc.

SEC Form 6-K filed by Adagene Inc.

$ADAG$MRK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Seidman Christine E

SEC Form 4 filed by Director Glocer Thomas H

SEC Form 4 filed by Director Coe Mary Ellen

$ADAG$MRK Market Insights

Live Market Insights

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

Merck Says Its Prophylactic Monoclonal Antibody Clesrovimab For Respiratory Syncytial Virus (RSV) Disease Met Its Primary Safety And Efficacy Endpoints

Merck Reports Results From Phase 2b/3 Trial Of Clesrovimab Antibody Designed To Protect Infants From Respiratory Syncytial Virus Disease; Says Clesrovimab Met All Primary Safety And Efficacy Endpoints

$ADAG$MRK Financials

Live finance-specific insights

Merck Announces First-Quarter 2025 Dividend

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Merck Announces Third-Quarter 2024 Financial Results

Recent Analyst Ratings for
$ADAG
$MRK

$ADAG
$MRK
Press Releases

$ADAG
$MRK
Large Ownership Changes

$ADAG
$MRK
Leadership Updates

$ADAG
$MRK
Analyst Ratings

$ADAG
$MRK
SEC Filings

$ADAG
$MRK
Insider Trading

$ADAG
$MRK
Market Insights

$ADAG
$MRK
Financials